Financial results for the period ended September 30, 2026
As filed · Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
EarningsMajormateriality 75 out of 100
What happened
FactFinancial results for the period ended September 30, 2026. Company along with Limited Review Report of the Statutory Auditors for the quarter and half year ended.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedEarlierQ1 FY27
EBITDA to PAT conversion at ~50%+
NowQ1 FY27
We expect gross margins to remain in the 58-60% range.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved 20.00%.confidence 60%
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Aspire to focus on North America Business Revenue of ~$375m by FY28 despite current external headwinds (management committed by FY28)
- Continue to add new customers in Europe by leveraging strong commercial presence and robust supply chain (management committed by FY27)
Evidence
- Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%